Form 4: Vanda Pharmaceuticals Director Tage Honore Receives Significant Restricted Stock Unit Grant

Vanda Pharmaceuticals Inc. Director Tage Honore was granted 59,225 restricted stock units, increasing his beneficial ownership to 123,469 shares, with vesting scheduled for June 5, 2026.

Summary

• Tage Honore, a Director of Vanda Pharmaceuticals Inc. (VNDA), was granted 59,225 shares of common stock in the form of a time-based Restricted Stock Unit (RSU) award.
• The transaction date for this acquisition was June 5, 2025.
• The shares were acquired at a price of $0, which is typical for an RSU grant.
• Following this transaction, Mr. Honore's direct beneficial ownership in Vanda Pharmaceuticals Inc. increased to 123,469 shares of common stock.
• The RSU award will vest 100% on June 5, 2026, contingent upon Mr. Honore's continuous service to the Issuer until that date.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a positive sign of aligning management interests with shareholder value and retaining key personnel. It is a standard compensation practice and generally viewed favorably.

Positives

• The grant of 59,225 Restricted Stock Units (RSUs) to Director Tage Honore aligns his interests with those of shareholders, as the value of the award is tied to the company's stock performance.
• The vesting schedule, requiring continuous service until June 5, 2026, acts as a retention mechanism for a key board member.
• An increase in a director's beneficial ownership to 123,469 shares demonstrates continued commitment and confidence in the company's future.

Negatives

• The issuance of new equity, even as RSUs, can lead to minor dilution for existing shareholders upon vesting, though this is a common and generally accepted aspect of equity compensation.

Risks

• The vesting of the Restricted Stock Units (RSUs) is contingent on the Reporting Person providing continuous service to the Issuer through the vesting date of June 5, 2026. If service is terminated before this date, the RSUs may be forfeited.

Future Outlook

The document indicates a future vesting event for the granted Restricted Stock Units on June 5, 2026, contingent on the director's continuous service, aligning future compensation with long-term company performance.

Industry Context

This transaction represents a routine equity compensation grant to a director, a common practice across the pharmaceutical and biotechnology industries to align executive and board interests with shareholder value and to incentivize long-term commitment and performance.

Related Party Transactions

• The grant of 59,225 Restricted Stock Units to Tage Honore, a Director of Vanda Pharmaceuticals Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value, as the value of the RSUs depends on the company's stock performance. There is a minor potential for dilution upon vesting, but this is generally considered a cost of aligning interests.
• Employees: No direct impact on general employees is mentioned, but it reinforces the company's compensation structure for leadership.

Next Steps

• The 59,225 Restricted Stock Units are scheduled to vest on June 5, 2026, provided Director Tage Honore continues his service to Vanda Pharmaceuticals Inc.

Key Dates

Recommendation

Keywords

Vanda Pharmaceuticals, VNDA, Restricted Stock Unit, RSU, Director Compensation, Insider Ownership, SEC Form 4, Equity Grant, Tage Honore